The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
March 28th 2024
The new indication includes pediatric patients aged 6 years and older who weigh at least 25 kg and have compensated liver disease.
Alcohol Consumption Not Found to Impact Sustained Virologic Response for Patients with Hepatitis C
October 3rd 2023The study investigators said that restricting access to direct-acting antiviral therapy due to alcohol consumption could create unnecessary barriers for those with hepatitis C virus.
Read More
Review of the 2022 ACCE Guidelines for Non-Alcoholic Fatty Liver Disease
November 10th 2022The most common cause of death for patients with non-alcoholic fatty liver disease is cardiovascular disease, but it also increases the risk of hepatocellular carcinoma and may surpass hepatitis B and C as the leading cause of this cancer.
Read More